Basel Medical Group Ltd

Basel Medical Group Ltd. (BMGL) is a British Virgin Islands-incorporated holding company ¹ with operations primarily conducted through its subsidiaries in Singapore ². The company specializes in a broad range of general and subspecialized orthopedic services, including trauma and sports medicine, knee/hip replacements, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments ³. Additionally, BMGL offers health screening, mental health, women's health, and general practice services ⁴. The company's business model is bifurcated into individual patient and corporate client segments, with fees determined by service type and medication prescribed, referencing Singapore Ministry of Health (MOH) fee benchmarks ⁵. BMGL's clinics are accredited by MediSave and are preferred providers for several insurance companies ⁶.

The company faces competition from both medical practitioners (orthopedists, neurosurgeons, neurologists, rheumatologists) and non-medical practitioners (traditional Chinese medicine physicians, physiotherapists, chiropractors) in Singapore ⁷. The orthopedic treatment market in Singapore is described as highly fragmented with low barriers to entry and low consolidation ⁸. BMGL's competitive advantages are stated to lie in the recognition of its brand names and trademarks, as well as the reputation of its specialist doctors ⁹. The company also emphasizes its integrated services within its micro-ecosystem, particularly for musculoskeletal-related diseases, and its integration into payor ecosystems such as insurers or national programs, along with the quality and continuity of care ¹⁰.

For the fiscal year ended June 30, 2025, BMGL reported total revenue of S$11,319,944 (US$8,900,027) ¹¹, an increase of approximately 12.6% from S$10,050,923 in the prior year ¹². This revenue growth was primarily driven by the newly acquired general practitioners clinic group, which contributed S$895,362 ¹³. Revenue from the orthopedic specialist clinic at Gleneagles increased by S$373,659, or approximately 3.7%, from S$10,050,923 in FY2024 to S$10,424,582 (US$8,196,071) in FY2025 ¹⁴. This increase in specialist clinic revenue was mainly due to a higher patient count from corporate clients, with revenue increasing by S$464,885 in FY2025 compared to FY2024, attributed to the rebound in the construction sector post-COVID ¹⁵. This was partially offset by a decrease of S$91,225 in revenue from individual walk-in patients ¹⁶. Other income saw a significant increase of S$641,174, or approximately 139.1%, from S$461,029 in FY2024 to S$1,102,203 (US$866,580) in FY2025, with the Bethesda group contributing S$220,133 ¹⁷.

The company recorded a loss before tax of S$12,505,497 (US$9,832,138) in FY2025, a substantial decrease from a profit of S$2,404,561 in FY2024 ¹⁸. This loss was mainly due to an impairment loss on goodwill of S$11,145,691 (US$8,763,025) recognized from the acquisition of the Bethesda group ¹⁹. Net loss after tax was S$12,088,104 (US$9,503,974) for FY2025, compared to a profit of S$2,072,800 in FY2024 ²⁰. Diluted EPS for FY2025 was (S$0.643) (US$0.506) ²¹, down from S$0.13 in FY2024 ²². Gross profit is not explicitly stated, but consumables, medical supplies, and other related expenses increased by S$278,113, or approximately 12.4%, to S$2,526,250 (US$1,986,201) in FY2025, in line with revenue growth ²³. Employee benefit expense increased by S$2,758,991, or approximately 75.8%, to S$6,397,933 (US$5,030,217) in FY2025, due to increased headcount and bonus payments, including additional staff from the Bethesda group ²⁴.

As of June 30, 2025, cash and cash equivalents amounted to S$2,979,083 (US$2,342,230) ²⁵. Total current assets were S$13,118,561 (US$10,314,145) ²⁶, and total non-current assets were S$3,736,060 (US$2,937,386) ²⁷. Total current liabilities were S$10,691,724 (US$8,406,105) ²⁸, and non-current liabilities were S$1,298,357 (US$1,020,801) ²⁹. Total equity was S$4,864,541 (US$3,824,625) ³⁰. Net cash used in operating activities was S$4,344,125 (US$3,415,460) in FY2025, a significant change from S$2,509,285 generated in FY2024 ³¹. Net cash used in investing activities was S$11,040,944 (US$8,680,671) in FY2025, primarily due to the acquisition of a new subsidiary for S$10,986,135 (US$8,637,578) ³². Net cash generated from financing activities was S$16,908,838 (US$13,294,157) in FY2025, mainly from share issuance proceeds of S$9,753,384 (US$7,668,358) ³³.

During the fiscal year, BMGL completed the acquisition of Bethesda Medical Pte. Ltd. on April 30, 2025, for a total consideration of US$8 million ³⁴. This acquisition added six general practice clinics in Singapore to the Group's operations ³⁵. The company also listed on NASDAQ in February 2025 ³⁶, issuing 2,205,000 ordinary shares at US$4.00 per share ³⁷, and an additional 330,750 ordinary shares at US$4.00 per share in March 2025 through an overallotment option ³⁸.

Management's specific revenue, margin, or EPS guidance for the upcoming period is not explicitly provided in the filing.

BMGL aims to grow into a more international medical group, transcending the role of a conventional healthcare provider with a vision for innovation, growth, and far-reaching impact ³⁹. The company's goal is to become the premier healthcare provider, offering seamless, one-stop solutions with unparalleled customer experience ⁴⁰. A key growth area is the continued expansion in Singapore to general practices and other specialized practices ⁴¹. The acquisition of Bethesda Medical Pte. Ltd., which operates six general practice clinics, is a direct step in this direction, broadening the company's service offerings ⁴².

Another significant growth vector involves expansion into other Southeast Asian countries ⁴³. The company is positioning itself as a key player in the region's evolving healthcare ecosystem by broadening its service offerings and integrating advanced medical solutions ⁴⁴. This geographic expansion is a stated strategic priority for future growth.

Regarding operational outlook, the company recognized a full impairment loss on the goodwill from the Bethesda group acquisition in FY2025, amounting to S$11,145,691 (US$8,763,025) ⁴⁵. This was done on a prudent basis as the newly acquired group's operations and performance had yet to be turned around ⁴⁶. The company intends to implement various measures to improve internal control over financial reporting, including hiring additional accounting personnel and establishing a financial and system control framework ⁴⁷. Regular IFRS and SEC financial reporting training programs for accounting and financial personnel are also planned ⁴⁸.

Planned capital allocation includes financing growth and operations through a combination of shareholders' equity, net cash generated from operating activities, and borrowings from financial institutions ⁴⁹. The principal uses of cash have been for operational expenses, working capital purposes, and payment of taxes ⁵⁰. The net offering proceeds from the initial public offering, approximately US$7,246,609, have been used mainly to acquire the Bethesda Group and for working capital for the current business ⁵¹.

Management explicitly flagged structural headwinds and execution risks related to the expected growth of demand for orthopedic treatment, the size and growth rate of its patient and customer base, and its ability to successfully compete in highly competitive industries and markets ⁵². Other factors include the regulatory environment and changes in laws, regulations or policies in the jurisdictions in which it operates, and the overall economic environment and general market and economic conditions in Singapore and globally ⁵³.

BMGL faces several material risks, including dependence on key medical practitioners and external medical professionals, which could lead to service disruptions and increased employee benefit expenses if replacements are not found or quality of service declines ⁵⁴. The company operates in a highly competitive healthcare market with low barriers to entry, facing competition from both private and government-owned hospitals and clinics, which could lead to pricing pressures and loss of market share ⁵⁵. Brand recognition and the reputation of specialist doctors are crucial, and any negative publicity or failure to protect intellectual property rights could adversely affect the business ⁵⁶. Operational disruptions at Gleneagles Medical Centre, where some clinics are located, or the loss of key corporate relationships that provide significant patient volume, could materially impact revenue and financial condition ⁵⁷. Increases in operating costs, particularly lease rental rates, and the risk of relocation, could disrupt business operations and affect profitability ⁵⁸. Credit risks from corporate clients, and limited control over the quality of products from external suppliers, also pose financial and reputational risks ⁵⁹. Technological disruptions, such as the proliferation of telemedicine, could reduce demand for in-clinic services and exert competitive pricing pressures ⁶⁰. Failures in medical equipment or IT systems, and cybersecurity risks related to handling personal and medical data, could lead to service disruptions, liability, and regulatory fines ⁶¹. Non-compliance with bank loan restrictions could result in default and adverse financial effects ⁶². Product liability lawsuits related to prescribed orthopedic devices could harm profitability and reputation ⁶³. Broader industry challenges, such as a slowdown in the Singapore economy leading to decreased demand for private healthcare, outbreaks of contagious diseases, and stricter healthcare regulations (including fee benchmarks and increased medical practitioner numbers), could negatively impact revenue and profitability ⁶⁴. Political, economic, and social developments in Singapore and the region, along with changes in laws, regulations, and licensing requirements, also present risks to current and future operations ⁶⁵.

Management's overall tone emphasizes a vision for innovation, growth, and far-reaching impact, aiming to transform BMGL into a premier international medical group offering seamless, one-stop solutions with unparalleled customer experience ⁶⁶. The strategic priorities for the period ahead include expanding in Singapore to general practices and other specialized practices, and venturing into other Southeast Asian countries ⁶⁷. This is evidenced by the recent acquisition of Bethesda Medical Pte. Ltd. to add general practice clinics ⁶⁸, and the incorporation of new entities like Eyetrust Medical Pte. Ltd. for eye specialist clinics and Chartered Imaging Pte. Ltd. for a new imaging center ⁶⁹. Management also highlighted the successful NASDAQ listing in February 2025, which raised approximately US$7,246,609 in net proceeds, primarily used for the Bethesda Group acquisition and working capital ⁷⁰. Despite recognizing a significant impairment loss on goodwill of S$11,145,691 (US$8,763,025) from the Bethesda acquisition due to its nascent operational turnaround ⁷¹, management remains committed to improving internal controls by hiring additional accounting personnel and establishing a robust financial and system control framework, alongside regular IFRS and SEC financial reporting training ⁷². The major shareholder, Rainforest Capital VCC, has committed to providing financial support for at least 12 months from the auditor's report date to ensure the company's going concern ⁷³.